<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782327</url>
  </required_header>
  <id_info>
    <org_study_id>2008/503</org_study_id>
    <nct_id>NCT00782327</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers</brief_title>
  <official_title>Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of losartan (an angiotensin receptor blocker-ARB) on aortic root growth
      in patients with Marfan syndrome, already treated with beta-blockers (BB). The effect of
      losartan will be compared to placebo. Losartan or placebo will be added to the treatment
      regimen in a two-step up-titration scheme over 2 weeks. Start doses of Losartan will be 25 mg
      for subjects under 50kg of weight and 50mg if the weight is over 50kg. Uptitration will be
      guided by the tolerance of the drug by the patients. Patients will be contacted by phone call
      for assessment of side-effects before second step of uptitration.

      Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if
      the weight is over 50kg
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease of rate of aortic root growth measured by echocardiography at level of sinuses of Valsalva. The measure will be expressed in mm of growth per year and as Z-score.</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative arterial stiffness</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of progression of aortic regurgitation</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic dissection incidence</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic root surgery</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of mitral regurgitation</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular size and function</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal and somatic traits</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphisms affecting clinical symptoms and response to treatment</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>At baseline and after 6 months, 1, 2 and 3 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic stiffness as assessed by MRI</measure>
    <time_frame>At baseline and after 1 year and 3 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily placebo capsule</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 10 years

          -  Diagnosis of MFS, according to the Ghent criteria and/or genetically proven FBN1
             mutations or linkage

          -  Consent obtained (written) either for the patient and for his/her parents (&lt;18y

          -  Z-score of the aorta at the level of the sinus of Valsalva ≥2 (BSA adjusted)

          -  ARB naïve patients

        Exclusion Criteria:

          -  Poor echocardiographic window,limiting the accurate measurement of the aortic root

          -  Contra-indication for ARB: Bilateral renal artery stenosis, renal function
             abnormalities (creatinine above normal for age), hyperkalemia

          -  Intolerance for ARB (eg angioedema)

          -  Pregnancy or breast feeding women

          -  Absence of effective contraception

          -  Liver function abnormalities

          -  Heart Failure

          -  Patients included in other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie De Backer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia De Nobele</last_name>
    <email>sylvia.denobele@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julie De Backer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

